Table 3 Compare the OSMC with other EOCs diagnosed from 2010 to 2019
From: Ovarian seromucinous carcinoma: an independent epithelial ovarian cancer?
Ovarian seromucinous Carcinoma (n = 12) | Ovarian endometrioid carcinoma (n = 24) | Ovarian serous carcinoma (n = 24) | Ovarian mucinous carcinoma (n = 24) | Ovarian Clear Cell Carcinoma (n = 22) ** | |
|---|---|---|---|---|---|
Age (years) | 46.83 ± 11.04 (23-68) | 46.83 ± 8.93 (24-63) | 47.33 ± 13.15 (21-69) | 46.88 ± 12.97 (24-70) | 51.5 ± 6.39 (39-67) |
Biomaker | |||||
CA125(U/ml) | |||||
<35 | 2 | 2 | 6 | 9 | 7 |
>35 | 10 | 22 | 18 | 15 | 15 |
CEA (ng/ml) | |||||
<5 | 9 | 23 | 20 | 18 | 17*** |
>5 | 3 | 1 | 4 | 6 | 1 |
CA125/CEA | |||||
>25 | 6 | 22* | 16* | 10 | 10 |
≤25 | 6 | 2 | 8 | 14 | 8 |
Ascites | |||||
Yes | 10 | 19 | 15 | 14 | 15 |
No | 2 | 5 | 9 | 10 | 7 |
FIGO stage | |||||
I-II | 10 | 19 | 20 | 18 | 15 |
III-IV | 2 | 5 | 4 | 6 | 7 |
Endometriosis | |||||
Yes | 0 | 3 | 0 | 2 | 4 |
No | 12 | 21 | 24 | 22 | 18 |
Residual lesions | |||||
<R1 | 11 | 23 | 22 | 20 | 20 |
>R1 | 0 | 1 | 2 | 4 | 2 |
None | 1 | 0 | 0 | 0 | 0 |
Response to Chemotherapy | |||||
Sensitivity | 10 | 19 | 17 | 15 | 15 |
Resistance | 1 | 0 | 4 | 4 | 3 |
None | 1 | 5 | 3 | 5 | 4 |
PFS (month) | 46.8 | 42.8 | 40 | 40 | 29.8 |
OS (month) | 50.2 | 46 | 46.4 | 42 | 31.4 |